Immunotherapy for the Treatment of Breast Cancer

Brenda Ernst, Karen Anderson

    Research output: Contribution to journalArticle

    33 Citations (Scopus)

    Abstract

    Decades of research are now leading to therapeutics that target the molecular mechanisms of the cancer-specific immune response. These therapeutics include tumor antigen vaccines, dendritic cell activators, adjuvants that activate innate immunity, adoptive cellular therapy, and checkpoint blockade. The advances in targeted immunotherapy have led to clinical advances in the treatment of solid tumors such as melanoma, prostate cancer, lung cancer, and hematologic malignancies. Preclinical and translational studies suggest that patients with breast cancer may also benefit from augmenting effective immune responses. These results have led to early-phase clinical trials of tumor antigen vaccines, adjuvants, and combinations of checkpoint inhibitor blockade to boost breast cancer-specific immunity in patients. This review focuses on the current and emerging development of cancer immunotherapy for breast cancer.

    Original languageEnglish (US)
    JournalCurrent Oncology Reports
    Volume17
    Issue number2
    DOIs
    StatePublished - 2015

    Fingerprint

    Immunotherapy
    Breast Neoplasms
    Cancer Vaccines
    Neoplasm Antigens
    Lung Neoplasms
    Hematologic Neoplasms
    Therapeutics
    Innate Immunity
    Dendritic Cells
    Immunity
    Melanoma
    Neoplasms
    Prostatic Neoplasms
    Clinical Trials
    Research

    Keywords

    • Immunotherapy
    • Tumor antigen
    • Tumor immunology
    • Vaccine

    ASJC Scopus subject areas

    • Oncology

    Cite this

    Immunotherapy for the Treatment of Breast Cancer. / Ernst, Brenda; Anderson, Karen.

    In: Current Oncology Reports, Vol. 17, No. 2, 2015.

    Research output: Contribution to journalArticle

    @article{dd2dc9f343a141edaf805986f109bb6e,
    title = "Immunotherapy for the Treatment of Breast Cancer",
    abstract = "Decades of research are now leading to therapeutics that target the molecular mechanisms of the cancer-specific immune response. These therapeutics include tumor antigen vaccines, dendritic cell activators, adjuvants that activate innate immunity, adoptive cellular therapy, and checkpoint blockade. The advances in targeted immunotherapy have led to clinical advances in the treatment of solid tumors such as melanoma, prostate cancer, lung cancer, and hematologic malignancies. Preclinical and translational studies suggest that patients with breast cancer may also benefit from augmenting effective immune responses. These results have led to early-phase clinical trials of tumor antigen vaccines, adjuvants, and combinations of checkpoint inhibitor blockade to boost breast cancer-specific immunity in patients. This review focuses on the current and emerging development of cancer immunotherapy for breast cancer.",
    keywords = "Immunotherapy, Tumor antigen, Tumor immunology, Vaccine",
    author = "Brenda Ernst and Karen Anderson",
    year = "2015",
    doi = "10.1007/s11912-014-0426-9",
    language = "English (US)",
    volume = "17",
    journal = "Current Oncology Reports",
    issn = "1523-3790",
    publisher = "Current Science, Inc.",
    number = "2",

    }

    TY - JOUR

    T1 - Immunotherapy for the Treatment of Breast Cancer

    AU - Ernst, Brenda

    AU - Anderson, Karen

    PY - 2015

    Y1 - 2015

    N2 - Decades of research are now leading to therapeutics that target the molecular mechanisms of the cancer-specific immune response. These therapeutics include tumor antigen vaccines, dendritic cell activators, adjuvants that activate innate immunity, adoptive cellular therapy, and checkpoint blockade. The advances in targeted immunotherapy have led to clinical advances in the treatment of solid tumors such as melanoma, prostate cancer, lung cancer, and hematologic malignancies. Preclinical and translational studies suggest that patients with breast cancer may also benefit from augmenting effective immune responses. These results have led to early-phase clinical trials of tumor antigen vaccines, adjuvants, and combinations of checkpoint inhibitor blockade to boost breast cancer-specific immunity in patients. This review focuses on the current and emerging development of cancer immunotherapy for breast cancer.

    AB - Decades of research are now leading to therapeutics that target the molecular mechanisms of the cancer-specific immune response. These therapeutics include tumor antigen vaccines, dendritic cell activators, adjuvants that activate innate immunity, adoptive cellular therapy, and checkpoint blockade. The advances in targeted immunotherapy have led to clinical advances in the treatment of solid tumors such as melanoma, prostate cancer, lung cancer, and hematologic malignancies. Preclinical and translational studies suggest that patients with breast cancer may also benefit from augmenting effective immune responses. These results have led to early-phase clinical trials of tumor antigen vaccines, adjuvants, and combinations of checkpoint inhibitor blockade to boost breast cancer-specific immunity in patients. This review focuses on the current and emerging development of cancer immunotherapy for breast cancer.

    KW - Immunotherapy

    KW - Tumor antigen

    KW - Tumor immunology

    KW - Vaccine

    UR - http://www.scopus.com/inward/record.url?scp=84923087112&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=84923087112&partnerID=8YFLogxK

    U2 - 10.1007/s11912-014-0426-9

    DO - 10.1007/s11912-014-0426-9

    M3 - Article

    VL - 17

    JO - Current Oncology Reports

    JF - Current Oncology Reports

    SN - 1523-3790

    IS - 2

    ER -